Scott Ratner, MD
Cardiology · Franklin Square, NYNPI 1932143997
Payments from drug & device makers
Across 433 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$1K
- Sanofi-aventis U.S. LLC$877
- Merck$764
- Abbott$661
- Pfizer$647
- plus $5K from 23 others
What the payments were for
- Consulting fees$5005%
- Food & beverage$9,04194%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 84 | $1,070 |
| Johnson & Johnson | 52 | $1,024 |
| Sanofi-aventis U.S. LLC | 42 | $877 |
| Merck | 40 | $764 |
| Abbott | 12 | $661 |
| Pfizer | 38 | $647 |
| Impulse Dynamics (USA) Inc. | 2 | $625 |
| Amarin Pharma, Inc. | 27 | $585 |
| Novo Nordisk | 22 | $515 |
| AstraZeneca | 22 | $440 |
| Medtronic(2 entities) | 4 | $410 |
| Scpharmaceuticals Inc. | 11 | $262 |
| Esperion Therapeutics, Inc. | 12 | $259 |
| E.r. Squibb & Sons, L.L.C. | 15 | $248 |
| Lexicon Pharmaceuticals, Inc. | 8 | $183 |
| Abiomed | 5 | $158 |
| Bayer | 6 | $140 |
| Amgen | 6 | $140 |
| Bridgebio Pharma, Inc. | 4 | $95 |
| Heartflow, Inc. | 4 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $76 |
| Kowa Pharmaceuticals America, Inc. | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $63 |
| Sanofi Pasteur Inc. | 3 | $62 |
| Boston Scientific | 2 | $51 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER SMART SYSTEM$625
- ASSURITY$141
- Confirm Rx$126
- Micra$122
- AVEIR$117
- Resolute$105
How this compares
$9,579 in reported general payments places this provider in the 85th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 255 | $339,779 |
| XareltoRivaroxaban | 171 | $236,929 |
| MultaqDronedarone Hcl | 103 | $195,617 |
| EntrestoSacubitril/Valsartan | 118 | $156,856 |
| FarxigaDapagliflozin Propanediol | 54 | $73,798 |
| BrilintaTicagrelor | 37 | $34,252 |
| MounjaroTirzepatide | 22 | $29,766 |
| JardianceEmpagliflozin | 25 | $21,738 |
| OzempicSemaglutide | 17 | $17,307 |
| WegovySemaglutide | 12 | $16,644 |
| Metoprolol Succinate | 723 | $13,392 |
| Prasugrel Hcl | 95 | $13,332 |
| Atorvastatin Calcium | 692 | $7,666 |
| Repatha PushtronexEvolocumab | 12 | $6,903 |
| Rosuvastatin Calcium | 341 | $5,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $647 | $339,779255 claims |
| Johnson & JohnsonXarelto | $1,024 | $236,929171 claims |
| Sanofi-aventis U.S. LLCMultaq | $877 | $195,617103 claims |
| NovartisEntresto | $1,070 | $156,856118 claims |
| AstraZenecaFarxiga, Brilinta | $440 | $108,05191 claims |
| Novo NordiskOzempic, Wegovy | $515 | $33,95129 claims |
| Lilly USA, LLCMounjaro | $14 | $29,76622 claims |
| Boehringer IngelheimJardiance | $22 | $21,73825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 cardiology providers in New York.
Other cardiology in Franklin Square
- Felix OviasuGarden City$150K
- David D'agateSmithtown$69K
- Michael AvaricioOzone Park$46K
- Michael SiegalNew York$43K
- Bimalkumar BrahmbhattAmityville$31K
- Michael HappesSmithtown$30K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
- Paul SapiaRoslyn$19K
- Salim BaghdadiKew Gardens$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.